ANA LUISA GARCIA CALICH
Projetos de Pesquisa
Unidades Organizacionais
FFM, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- The anti-ribosomal P antibodies and prognosis in autoimmune hepatitis(2014) CALICH, Ana L.; BONFA, Eloisa
- LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area(2014) BONFIGLIOLI, K. R.; RIBEIRO, A. C. M.; MORAES, J. C. B.; SAAD, C. G. S.; SOUZA, F. H. C.; CALICH, A. L.; BONFA, E.; LAURINDO, I. M. M.SETTING: Recommendations for screening for latent tuberculous infection (LTBI) in patients eligible for antitumour necrosis factor (TNF) agents remain unclear in endemic regions. OBJECTIVE: To evaluate the long-term efficacy of LTBI screening and treatment in patients with rheumatoid arthritis (RA) receiving TNF blockers. DESIGN: A total of 202 RA patients were screened for LTBI before receiving anti-TNF treatment Using the tuberculin skin test (TST), chest X-ray (CXR) and history of exposure to tuberculosis (TB). All subjects were regularly followed at 1- to 3-month intervals. RESULTS: Eighty-five patients (42%) were treated with a single anti-TNF agent, while 117 patients (58%) changed anti-TNF agents once or twice. LTBI screening was positive in 66 patients, 44 were TST-positive, 23 had a history of TB exposure and 14 had an abnormal CXR. Exposure alone accounted for LTBI diagnosis in 14 patients with a negative TST. LTBI patients were treated with isoniazid (300 mg/day) for 6 months, and none developed TB. During follow-up, TST was repeated in 51 patients. Conversion was observed in 5; 3 were diagnosed with LTBI and 2 with active TB respectively 14 and 36 months after receiving anti-TNF treatment, suggesting new TB exposure. CONCLUSION: LTBI screening and treatment before anti-TNF treatment is effective in endemic areas and reinforces the importance of establishing contact history for diagnosing LTBI in RA patients.
- Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients(2014) CALICH, Ana Luisa; PUECHAL, Xavier; PUGNET, Gregory; LONDON, Jonathan; TERRIER, Benjamin; CHARLES, Pierre; MOUTHON, Luc; GUILLEVIN, LoicThe aim of this study was to evaluate the efficacy and safety of rituximab (RTX) associated with glucocorticoid treatment based on disease severity, as a remission induction treatment for granulomatosis with polyangiitis (GPA) (Wegener's) and to analyze the results of long-term maintenance therapy with low doses of RTX in a routine time-based protocol. This single-center retrospective study used standardized data collection from all CPA patients receiving RTX between 2002 and 2013. The remission induction regimen consisted of RTX and gluco-corticoids, adapted according to disease severity. Once remission was achieved, patients received RTX maintenance treatment (500 mg every 6 months) for 18 months. Sixty-six CPA patients received RTX for remission induction. After six months, a response had been achieved in 78.8% of these patients, with a moderate oral prednisone regimen (mean dose at baseline, 32.8 +/- 23.4 mg/day). Subglottic stenosis increased the risk of treatment failure (OR = 312, P = 0.0104). RTX maintenance treatment was continued for 18 months in 92% of the CPA patients, who were followed for 34.2 +/- 26.2 months (mean total cumulative RTX dose of 4.6 +/- 1.7 g). The relapse rate was 11.2/100 patient-years. The relapses occur a mean of 13.5 +/- 14.7 months after the last ""RTX infusion. Twenty-one severe adverse events were recorded; 13.6% patients had severe infections. We conclude that in this single-center cohort, RTX associated with glucocorticoid treatment adapted for disease severity appeared to induce remission effectively in CPA patients. Maintenance treatment with low doses of RTX in a routine time-based protocol was safe and associated with low rates of relapse on treatment.
- LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area (vol 18, pg 905, 2014)(2014) BONFIGLIOLI, K. R.; RIBEIRO, A. C. M.; MORAES, J. C. B.; SAAD, C. G. S.; SOUZA, F. H. C.; CALICH, A. L.; BONFA, E.; LAURINDO, I. M. M.
bookPart Síndromes vasculíticas(2014) CALICH, Ana Luisa Garcia; CALICH, Isidio